Is Elicio Therapeutics (ELTX) Stock Halal?
Compliance Status
Not Halal
Screened on Nov 10, 2026 · AAOIFI Standard 21
Non-Compliant
Is Elicio Therapeutics, Inc. (ELTX) halal? Not Halal. Based on AAOIFI screening, Elicio Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).
Quote this verdict
HalalScreener rates Elicio Therapeutics, Inc. (ELTX) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 10, 2026. Source: https://halalscreener.app/en/stock/ELTX
Business activity
What the company sells is permissible.
Company debt
Over the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
Most scholars advise not holding ELTX
It does not pass AAOIFI Shariah screening.
See halal alternatives from the same sector further down this page
Share this verdict
A receipt-style image with the math on it, so whoever you send it to can check it.

ELTX
Elicio Therapeutics, Inc.
$1.59
Market Cap: 30.3M
Get an email if ELTX's halal status changes
We re-screen Elicio Therapeutics, Inc. daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Sector: Healthcare · Industry: Biotechnology
Why this does not pass
- Interest-bearing debt is 31.9% of market cap, over the 30% AAOIFI limit.
- Interest-bearing deposits are over the 30% limit.
Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.
Shariah Compliance Status
Compliance History
Not Halalnow
since Aug 2026
Under Review
until the change above
Tracked since Aug 2026. Updates automatically on each re-screen.
Halal Alternatives in Healthcare
This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:
More Healthcare Stocks
Know the day ELTX's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is Elicio Therapeutics, Inc. (ELTX) halal to invest in?
Why did Elicio Therapeutics, Inc. get a F compliance rating?
What could change Elicio Therapeutics, Inc.'s Shariah verdict?
How often is Elicio Therapeutics, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.
